CNTB News and Press, Connect Biopharma Holdings Limited From 06/05/23

2023-06-05 08:14:50 ET Bellerophon Therapeutic ( BLPH ) -71% announces top-line data from phase 3 REBUILD clinical trial of INOpulse® for treatment of fibrotic interstitial lung disease. Mallinckrodt MNK -18% to consider filing for bankruptcy again - WSJ. ...

2023-06-05 06:00:00 ET 3 Tips to Develop a Risk Management Strategy for Trading Penny Stocks Trading penny stocks can offer an exciting avenue for investors seeking significant returns in a short period. As with any investment, a keen understanding of risk management is key to navigatin...

2023-06-04 11:00:00 ET 3 Things to Consider For Understanding Liquidity With Penny Stocks Penny stocks offer an intriguing opportunity for investors due to their low price and potential for substantial returns. However, understanding liquidity is vital to navigate the realm of penny s...

2023-06-04 07:30:00 ET Summary Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for t...

2023-06-02 10:07:42 ET Connect Biopharma ( NASDAQ: CNTB ) added ~17% in the morning hours Friday after announcing long-term data from its Phase 2 trial for ulcerative colitis candidate icanbelimod, previously known as CBP-307. Citing data from a maintenance period in the tri...

2023-06-02 10:02:23 ET Gainers: Connect Biopharma ( CNTB ) +26% . LAVA Therapeutics ( LVTX ) +19% . Panbela Therapeutics ( PBLA ) +18% . Apollomics ( APLM ) +15% .  Rockwell Medical ( RMTI ) +10% . Losers: Kiora Pharm...

Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction period. Icanbelimod continued to be well-tolerated, consistent with observed induction period safety d...

2023-04-11 16:24:52 ET Connect Biopharma press release ( NASDAQ: CNTB ): FY GAAP EPS of -$2.10 misses by $0.03 . Cash, equivalents, and short-term and long-term investments were RMB 1,127.3 million (USD 161.9 million) as of December 31, 2022, compared with RMB 1,706.9 ...

CDE’s Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track for NDA Submission in China by End of First Quarter 2024 SAN DIEGO and TAICANG, SUZHOU, China, April 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the...

2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...